Bayer : Announces KERENDIA® (finerenone) Reduces the Risk of Cardiovascular Outcomes in New Phase III FIGARO-DKD Study in Adults With Chronic Kidney Disease (Stages 1-4) Associated With Type 2 Diabetes marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Finerenone reduces the risk of cardiovascular morbidity and mortality in patients with mild-to-moderate kidney disease and type 2 diabetes. That’s the..